Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Astrazeneca Plc (NY: AZN)
47.62 USD  -0.58 (-1.20%)
Official Closing Price  /  Updated: 6:30 PM EST, Dec 5, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,302,400
Open 48.07
Bid (Size) 45.00 (1)
Ask (Size) 59.92 (1)
Prev. Close 48.20
Today's Range 47.51 - 48.09
52wk Range 35.30 - 49.22
Shares Outstanding 2,533,294,824
Dividend Yield 2.88%
Performance
YTD
+25.98%
+25.98%
1 Month
+0.89%
+0.89%
3 Month
+6.39%
+6.39%
6 Month
+22.64%
+22.64%
1 Year
+22.51%
+22.51%
Top News
More News
Advanced Medical Technologies Help Stem the Evergrowing Spread of Ailments
FinancialBuzz.com News Commentary Read More
from PR Newswire
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
AstraZeneca and Merck/MSD were approved to sell their jointly marketed PARP inhibitor in China as a first-line maintenance treatment for BRCA-mutated ovarian cancer. In a Phase III trial among patients... Read More
from ChinaBio® Today
More News
Read More
REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
category companyNews
from Reuters: Company News
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
from ChinaBio® Today
AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
category companyNews
from Reuters: Company News
China to use drug bulk-buy program to close price gap
category companyNews
from Reuters: Company News
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
category TECD , Futures , Benzinga , and 11 more.
from Benzinga
Is Clovis Oncology Really a Buyout Candidate?
category Market News , JNJ , CLVS , and 3 more.
from Motley Fool
China Adds 70 Drugs to Insurance Reimbursement List; Negotiates 61% Average Price Cuts
from ChinaBio® Today
UPDATE 1-AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer
category companyNews
from Reuters: Company News
Here's Why Lexicon Pharmaceuticals Is Tumbling Today
category LXRX , MRK , AZN , and 5 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.